{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:42:41Z","timestamp":1783539761070,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T00:00:00Z","timestamp":1340755200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s10238-012-0192-7","type":"journal-article","created":{"date-parts":[[2012,8,21]],"date-time":"2012-08-21T15:37:07Z","timestamp":1345563427000},"page":"177-186","source":"Crossref","is-referenced-by-count":26,"title":["Negative effect of immunosuppressive therapy in the performance of the QuantiFERON Gold In-Tube test in patients with immune-mediated inflammatory diseases"],"prefix":"10.1007","volume":"13","author":[{"given":"Jos\u00e9 M.","family":"Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Masi\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalina","family":"Robledano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Navarro-Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Matarredona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana F.","family":"Garc\u00eda-Sepulcre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,27]]},"reference":[{"key":"192_CR1","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/gut.2006.114660","volume":"57","author":"N Viget","year":"2008","unstructured":"Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF (2008) Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 57:549\u2013558","journal-title":"Gut"},{"key":"192_CR2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.md.0000180044.19285.9a","volume":"84","author":"NF Crum","year":"2005","unstructured":"Crum NF, Lederman ER, Wallace MR (2005) Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 84:291\u2013302","journal-title":"Medicine (Baltimore)"},{"key":"192_CR3","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","volume":"57","author":"JJ G\u00f3mez-Reino","year":"2007","unstructured":"G\u00f3mez-Reino JJ, Carmona L, Angel Descalzo M, Biobadaser Group (2007) Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthr Rheum 57:756\u2013761","journal-title":"Arthr Rheum"},{"key":"192_CR4","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/rheumatology\/kei103","volume":"44","author":"J Ledingham","year":"2005","unstructured":"Ledingham J, Wilkinson C, Deighton C (2005) British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-\u03b1 treatments. Rheumatology (Oxford) 44:1205\u20131206","journal-title":"Rheumatology (Oxford)"},{"key":"192_CR5","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","volume":"52","author":"L Carmona","year":"2005","unstructured":"Carmona L, G\u00f3mez-Reino JJ, Rodr\u00edguez-Valverde V, Montero D, Pascual-G\u00f3mez E, Mola EM, BIOBADASER Group et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthr Rheum 52:1766\u20131772","journal-title":"Arthr Rheum"},{"key":"192_CR6","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/ard.2004.029041","volume":"64","author":"D Ponce de Le\u00f3n","year":"2005","unstructured":"Ponce de Le\u00f3n D, Acevedo-V\u00e1squez E, S\u00e1nchez-Torres A, Cucho M, Alfaro J, Perich R et al (2005) Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 64:1360\u20131361","journal-title":"Ann Rheum Dis"},{"key":"192_CR7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1542-3565(04)00060-6","volume":"2","author":"WS Mow","year":"2004","unstructured":"Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA (2004) High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2:309\u2013313","journal-title":"Clin Gastroenterol Hepatol"},{"key":"192_CR8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.eimc.2009.05.012","volume":"28","author":"A Lalvani","year":"2010","unstructured":"Lalvani A, Pareek M (2010) Interferon gamma release assays: principles and practice. Enferm Infecc Microbiol Clin 28:245\u2013252","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"192_CR9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","volume":"149","author":"M Pai","year":"2008","unstructured":"Pai M, Zwerling A, Menzies D (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149:177\u2013184","journal-title":"Ann Intern Med"},{"key":"192_CR10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1183\/09031936.00115110","volume":"37","author":"R Diel","year":"2011","unstructured":"Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B et al (2011) Interferon-\u03b3 release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 37:88\u201399","journal-title":"Eur Respir J"},{"key":"192_CR11","unstructured":"Cellestis Limited QuantiFERON-TB Gold. Available at: http:\/\/www.cellestis.com . Accessed 20 February 2011"},{"key":"192_CR12","unstructured":"Mazurek M, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, IGRA Expert Committee, Centers for Disease Control and Prevention (CDC) (2010) Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection\u2014United States, 2010. MMWR Recomm Rep 59(RR-5):1\u201325"},{"key":"192_CR13","doi-asserted-by":"crossref","unstructured":"Sellam J, Hamdi H, Roy C, Baron G, Lemann M, Pu\u00e9chal X, RATIO (Research Axed on Tolerance of Biotherapies) Study Group et al. (2007) Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 66:1610\u20131615","DOI":"10.1136\/ard.2007.069799"},{"key":"192_CR14","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s10096-008-0519-1","volume":"27","author":"M Bocchino","year":"2008","unstructured":"Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Santoro G, Balato N et al (2008) Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 27:907\u2013913","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"192_CR15","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1111\/j.1572-0241.2008.02050.x","volume":"103","author":"AM Schoepfer","year":"2008","unstructured":"Schoepfer AM, Flogerzi B, Fallegger S, Schaffer T, Mueller S, Nicod L, Seibold F (2008) Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 103:2799\u20132806","journal-title":"Am J Gastroenterol"},{"key":"192_CR16","first-page":"776","volume":"35","author":"D Ponce de Leon","year":"2008","unstructured":"Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J et al (2008) Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 35:776\u2013781","journal-title":"J Rheumatol"},{"key":"192_CR17","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.23705","volume":"59","author":"DY Chen","year":"2008","unstructured":"Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL (2008) Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthr Rheum 59:800\u2013806","journal-title":"Arthr Rheum"},{"key":"192_CR18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/ard.2008.101857","volume":"69","author":"J Martin","year":"2010","unstructured":"Martin J, Walsh C, Gibbs A, McDonnell T, Fearon U, Keane J et al (2010) Comparison of interferon gamma release assays and conventional screening tests before tumour necrosis factor alpha blockade in patients with inflammatory arthritis. Ann Rheum Dis 69:181\u2013185","journal-title":"Ann Rheum Dis"},{"key":"192_CR19","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.3899\/jrheum.090268","volume":"36","author":"N Inanc","year":"2009","unstructured":"Inanc N, Aydin SZ, Karakurt S, Atagunduz P, Yavuz S, Direskeneli H (2009) Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 36:2675\u20132681","journal-title":"J Rheumatol"},{"key":"192_CR20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s10165-009-0226-5","volume":"20","author":"T Maeda","year":"2010","unstructured":"Maeda T, Banno S, Maeda S, Naniwa T, Hayami Y, Watanabe M, Itoh R, Sato S, Ueda R (2010) Usefulness and limitations of QuantiFERON-TB Gold in Japanese rheumatoid arthritis patients: proposal to decrease the lower cutoff level for assessing latent tuberculosis infection. Mod Rheumatol 20:18\u201323","journal-title":"Mod Rheumatol"},{"key":"192_CR21","first-page":"553","volume":"164","author":"HY Chiu","year":"2011","unstructured":"Chiu HY, Hsueh PR, Tsai TF (2011) Clinical experience of QuantiFERON(\u00ae) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan. Br J Dermatol 164:553\u2013559","journal-title":"Br J Dermatol"},{"key":"192_CR22","doi-asserted-by":"crossref","unstructured":"B\u00e9lard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK et al. (2011) Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis. doi: 10.1002\/ibd.21605","DOI":"10.1002\/ibd.21605"},{"key":"192_CR23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ibd.21329","volume":"7","author":"BJ Qumseya","year":"2011","unstructured":"Qumseya BJ, Ananthakrishnan AN, Skaros S, Bonner M, Issa M, Zadvornova Y et al (2011) QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflamm Bowel Dis 7:77\u201383","journal-title":"Inflamm Bowel Dis"},{"key":"192_CR24","unstructured":"Chang B, Park HY, Jeon K, Ahn JK, Cha HS, Koh EM et al. (2011) Interferon-\u03b3 release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. Clin Rheumatol. doi: 10.1007\/s10067-011-1771-1779"},{"key":"192_CR25","doi-asserted-by":"crossref","unstructured":"Maeda T, Banno S, Maeda S, Naniwa T, Hayami Y, Watanabe M et al. (2011) Comparison of QuantiFERON-TB Gold and the tuberculin skin test for detecting previous tuberculosis infection evaluated by chest CT findings in Japanese rheumatoid arthritis patients. J Infect Chemother. doi: 10.1007\/s10156-011-0250-1","DOI":"10.1007\/s10156-011-0250-1"},{"key":"192_CR26","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2133.2009.09505.x","volume":"161","author":"CH Smith","year":"2009","unstructured":"Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, Chair of Guideline Group et al (2009) British Association of Dermatologists\u2019 guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 161:987\u20131019","journal-title":"Br J Dermatol"},{"key":"192_CR27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-0029-1214673","volume":"63","author":"R Diel","year":"2009","unstructured":"Diel R, Hauer B, Loddenkemper R, Manger B, Kr\u00fcger K (2009) Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Pneumologie 63:329\u2013334","journal-title":"Pneumologie"},{"key":"192_CR28","first-page":"620","volume":"137","author":"C Beglinger","year":"2007","unstructured":"Beglinger C, Dudler J, Mottet C, Nicod L, Seibold F, Villiger PM et al (2007) Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 137:620\u2013622","journal-title":"Swiss Med Wkly"},{"key":"192_CR29","doi-asserted-by":"crossref","unstructured":"American Thoracic Society: Centers for Disease Control and Prevention (2000) Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Car Med 161:1376\u20131395","DOI":"10.1164\/ajrccm.161.4.16141"},{"key":"192_CR30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GC (1977) The measurement of observer agreement for categorical data. Biometrics 33:159\u2013174","journal-title":"Biometrics"},{"key":"192_CR31","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3899\/jrheum.081292","volume":"36","author":"B Soborg","year":"2009","unstructured":"Soborg B, Ruhwald M, Hetland ML, Jacobsen S, Andersen AB, Milman N et al (2009) Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J Rheumatol 36:1876\u20131884","journal-title":"J Rheumatol"},{"key":"192_CR32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10238-009-0082-9","volume":"10","author":"F Gogus","year":"2010","unstructured":"Gogus F, G\u00fcnendi Z, Karakus R, Erdogan Z, Hizel K, Atalay F (2010) Comparison of tuberculin skin test and QuantiFERON-TB gold in tube test in patients with chronic inflammatory diseases living in a tuberculosis endemic population. Clin Exp Med 10:173\u2013177","journal-title":"Clin Exp Med"},{"key":"192_CR33","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.070789","volume":"67","author":"G Matulis","year":"2008","unstructured":"Matulis G, J\u00fcni P, Villiger PM, Gadola SD (2008) Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 67:84\u201390","journal-title":"Ann Rheum Dis"},{"key":"192_CR34","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/ard.2009.113829","volume":"69","author":"S Kleinert","year":"2010","unstructured":"Kleinert S, Kurzai O, Elias J, Marten K, Engelke C, Feuchtenberger M et al (2010) Comparison of two interferon-gamma release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases. Ann Rheum Dis 69:782\u2013784","journal-title":"Ann Rheum Dis"},{"key":"192_CR35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/1471-2334-9-207","volume":"9","author":"EY Kim","year":"2007","unstructured":"Kim EY, Lim JE, Jung JY, Son JY, Lee KJ, Yoon YW et al (2007) Performance of the tuberculin skin test and interferon-gamma release assay for detection of tuberculosis infection in immunocompromised patients in a BCG-vaccinated population. BMC Infect Dis 9:207","journal-title":"BMC Infect Dis"},{"key":"192_CR36","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4049\/jimmunol.0801998","volume":"183","author":"TJ Creed","year":"2009","unstructured":"Creed TJ, Lee RW, Newcomb PV, di Mambro AJ, Raju M, Dayan CM (2009) The effects of cytokines on suppression of lymphocyte proliferation by dexamethasone. J Immunol 183:164\u2013171","journal-title":"J Immunol"},{"key":"192_CR37","first-page":"46","volume":"29","author":"A De","year":"2002","unstructured":"De A, Blotta HM, Mamoni RL, Louzada P, Bertolo MB, Foss NT et al (2002) Effects of dexamethasone on lymphocyte proliferation and cytokine production in rheumatoid arthritis. J Rheumatol 29:46\u201351","journal-title":"J Rheumatol"},{"key":"192_CR38","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1097\/01.aids.0000191923.08938.5b","volume":"19","author":"K Dheda","year":"2005","unstructured":"Dheda K, Lalvani A, Miller RF, Scott G, Booth H, Johnson MA et al (2005) Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS 19:2038\u20132041","journal-title":"AIDS"},{"key":"192_CR39","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2249.2007.03477.x","volume":"150","author":"SA Clark","year":"2007","unstructured":"Clark SA, Martin SL, Pozniak A, Steel A, Ward B, Dunning J et al (2007) Tuberculosis antigen-specific immune responses can be detected using enzyme-linked immunospot technology in human immunodeficiency virus (HIV)-1 patients with advanced disease. Clin Exp Immunol 150:238\u2013244","journal-title":"Clin Exp Immunol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-012-0192-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-012-0192-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-012-0192-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T21:06:18Z","timestamp":1562101578000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-012-0192-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,27]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["192"],"URL":"https:\/\/doi.org\/10.1007\/s10238-012-0192-7","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"value":"1591-8890","type":"print"},{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,27]]}}}